These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30992552)

  • 1. Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result.
    Leof ER; Zhu X; Rabe KG; McCormick JB; Petersen GM; Radecki Breitkopf C
    Genet Med; 2019 Nov; 21(11):2468-2477. PubMed ID: 30992552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychological Impact of Learning CDKN2A Variant Status as a Genetic Research Result.
    Zhu X; Leof ER; Rabe KG; McCormick JB; Petersen GM; Radecki Breitkopf C
    Public Health Genomics; 2018; 21(3-4):154-163. PubMed ID: 30999302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome.
    Aspinwall LG; Taber JM; Leaf SL; Kohlmann W; Leachman SA
    Psychooncology; 2013 Feb; 22(2):276-89. PubMed ID: 23382133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attitudes toward genetic testing, family planning and preimplantation genetic testing in families with a germline CDKN2A pathogenic variant.
    Onnekink AM; Klatte DCF; van Hooft JE; van den Berg SH; van der Zwaan SMS; van Doorn R; Hinnen SCH; Potjer TP; Bleiker EMA; van Leerdam ME
    Fam Cancer; 2024 Aug; 23(3):255-265. PubMed ID: 38822936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk.
    Aspinwall LG; Stump TK; Taber JM; Drummond DM; Kohlmann W; Champine M; Leachman SA
    Transl Behav Med; 2018 Jan; 8(1):29-43. PubMed ID: 29385581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors.
    Glanz K; Volpicelli K; Kanetsky PA; Ming ME; Schuchter LM; Jepson C; Domchek SM; Armstrong K
    Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):607-14. PubMed ID: 23392000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Priority of Risk (But Not Perceived Magnitude of Risk) Predicts Improved Sun-Protection Behavior Following Genetic Counseling for Familial Melanoma.
    Taber JM; Aspinwall LG; Drummond DM; Stump TK; Kohlmann W; Champine M; Cassidy P; Leachman SA
    Ann Behav Med; 2021 Feb; 55(1):24-40. PubMed ID: 32415830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic test reporting enhances understanding of risk information and acceptance of prevention recommendations compared to family history-based counseling alone.
    Taber JM; Aspinwall LG; Stump TK; Kohlmann W; Champine M; Leachman SA
    J Behav Med; 2015 Oct; 38(5):740-53. PubMed ID: 26178773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
    McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
    Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of melanoma genetic test reporting on perceived control over melanoma prevention.
    Aspinwall LG; Stump TK; Taber JM; Kohlmann W; Leaf SL; Leachman SA
    J Behav Med; 2015 Oct; 38(5):754-65. PubMed ID: 25822116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families.
    Aspinwall LG; Leaf SL; Dola ER; Kohlmann W; Leachman SA
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1510-9. PubMed ID: 18559569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
    Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S
    J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disclosing individual CDKN2A research results to melanoma survivors: interest, impact, and demands on researchers.
    Christensen KD; Roberts JS; Shalowitz DI; Everett JN; Kim SY; Raskin L; Gruber SB
    Cancer Epidemiol Biomarkers Prev; 2011 Mar; 20(3):522-9. PubMed ID: 21307304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDKN2A testing and genetic counseling promote reductions in objectively measured sun exposure one year later.
    Stump TK; Aspinwall LG; Drummond DM; Taber JM; Kohlmann W; Champine M; Cassidy PB; Petrie T; Liley B; Leachman SA
    Genet Med; 2020 Jan; 22(1):26-34. PubMed ID: 31371819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families.
    Kasparian NA; Meiser B; Butow PN; Simpson JM; Mann GJ
    Genet Med; 2009 Apr; 11(4):265-78. PubMed ID: 19265718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic
    Overbeek KA; Rodríguez-Girondo MD; Wagner A; van der Stoep N; van den Akker PC; Oosterwijk JC; van Os TA; van der Kolk LE; Vasen HFA; Hes FJ; Cahen DL; Bruno MJ; Potjer TP
    J Med Genet; 2021 Apr; 58(4):264-269. PubMed ID: 32482799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perceptions of genetic research and testing among members of families with an increased risk of malignant melanoma.
    Bränström R; Kasparian NA; Affleck P; Tibben A; Chang YM; Azizi E; Baron-Epel O; Bergman W; Chan M; Davies J; Ingvar C; Kanetsky PA; van Leeuwen E; Olsson H; Gruis NA; Brandberg Y; Newton-Bishop J
    Eur J Cancer; 2012 Nov; 48(16):3052-62. PubMed ID: 22726816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
    Horn IP; Marks DL; Koenig AN; Hogenson TL; Almada LL; Goldstein LE; Romecin Duran PA; Vera R; Vrabel AM; Cui G; Rabe KG; Bamlet WR; Mer G; Sicotte H; Zhang C; Li H; Petersen GM; Fernandez-Zapico ME
    J Biol Chem; 2021; 296():100634. PubMed ID: 33823155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Test Reporting and Counseling for Melanoma Risk in Minors May Improve Sun Protection Without Inducing Distress.
    Stump TK; Aspinwall LG; Kohlmann W; Champine M; Hauglid J; Wu YP; Scott E; Cassidy P; Leachman SA
    J Genet Couns; 2018 Aug; 27(4):955-967. PubMed ID: 29349527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma.
    Peters MLB; Stobie L; Dudley B; Karloski E; Allen K; Speare V; Dolinsky JS; Tian Y; DeLeonardis K; Krejdovsky J; Button A; Lim C; Borazanci E; Brand R; Tung N
    Cancer; 2019 Jul; 125(14):2488-2496. PubMed ID: 30980401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.